These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 21487418)

  • 41. Tamoxifen unsuitable for primary prevention of breast cancer: uncertain efficacy, clear risks.
    Prescrire Int; 2000 Apr; 9(46):56-8. PubMed ID: 11503791
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Decision analysis of tamoxifen for the prevention of invasive breast cancer.
    Grann VR; Sundararajan V; Jacobson JS; Whang W; Heitjan DF; Antman KH; Neugut AI
    Cancer J; 2000; 6(3):169-78. PubMed ID: 10882333
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites.
    Liu X; Pisha E; Tonetti DA; Yao D; Li Y; Yao J; Burdette JE; Bolton JL
    Chem Res Toxicol; 2003 Jul; 16(7):832-7. PubMed ID: 12870885
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The selective estrogen receptor modulators (SERMs) raloxifene and tamoxifen improve ANP levels and decrease nuclear translocation of NF-kB in estrogen-deficient rats.
    Lamas AZ; Nascimento AM; Medeiros ARS; Caliman IF; Dalpiaz PLM; Firmes LB; Sousa GJ; Oliveira PWC; Andrade TU; Reis AM; Gouvea SA; Bissoli NS
    Pharmacol Rep; 2017 Aug; 69(4):798-805. PubMed ID: 28591668
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Estrogen dependent growth inhibitory effects of tamoxifen but not genistein in solid tumors derived from estrogen receptor positive (ER+) primary breast carcinoma MCF7: single agent and novel combined treatment approaches.
    Nobert GS; Kraak MM; Crawford S
    Bull Cancer; 2006 Jul; 93(7):E59-66. PubMed ID: 16873071
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid.
    Fagerlin A; Zikmund-Fisher BJ; Nair V; Derry HA; McClure JB; Greene S; Stark A; Hensley Alford S; Lantz P; Hayes DF; Wiese C; Claud Zweig S; Pitsch R; Jankovic A; Ubel PA
    Breast Cancer Res Treat; 2010 Feb; 119(3):613-20. PubMed ID: 19908143
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effect of tamoxifen on the endometrium.
    Barakat RR
    Oncology (Williston Park); 1995 Feb; 9(2):129-34; discussion 139-40, 142. PubMed ID: 8771096
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Patient reluctance toward tamoxifen use for breast cancer primary prevention.
    Port ER; Montgomery LL; Heerdt AS; Borgen PI
    Ann Surg Oncol; 2001 Aug; 8(7):580-5. PubMed ID: 11508619
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Short-term tamoxifen treatment has long-term effects on metabolism in high-fat diet-fed mice with involvement of Nmnat2 in POMC neurons.
    Liu Z; Cheng Y; Luan Y; Zhong W; Lai H; Wang H; Yu H; Yang Y; Feng N; Yuan F; Huang R; He Z; Zhang F; Yan M; Yin H; Guo F; Zhai Q
    FEBS Lett; 2018 Oct; 592(19):3305-3316. PubMed ID: 30192985
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prescribing tamoxifen in primary care for the prevention of breast cancer: a national online survey of GPs' attitudes.
    Smith SG; Foy R; McGowan JA; Kobayashi LC; de Censi A; DeCensi A; Brown K; Side L; Cuzick J
    Br J Gen Pract; 2017 Jun; 67(659):e414-e427. PubMed ID: 28193617
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The cost effectiveness of tamoxifen in the prevention of breast cancer.
    Noe LL; Becker RV; Gradishar WJ; Gore M; Trotter JP
    Am J Manag Care; 1999 Jun; 5(6 Suppl):S389-406. PubMed ID: 10538851
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predicting adherence to tamoxifen for breast cancer adjuvant therapy and prevention.
    Lin JH; Zhang SM; Manson JE
    Cancer Prev Res (Phila); 2011 Sep; 4(9):1360-5. PubMed ID: 21893499
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Breast cancer: tamoxifen - offering a long-term prevention option.
    Errico A
    Nat Rev Clin Oncol; 2015 Feb; 12(2):66. PubMed ID: 25583681
    [No Abstract]   [Full Text] [Related]  

  • 54. Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"--20 years as a target for the treatment and prevention of cancer.
    Jordan VC
    Breast Cancer Res Treat; 1995; 36(3):267-85. PubMed ID: 8573710
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of tamoxifen in the treatment and prevention of breast cancer.
    Jordan VC
    Curr Probl Cancer; 1992; 16(3):129-76. PubMed ID: 1582240
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tamoxifen effects on menopause--associated risk factors and symptoms.
    Benshushan A; Brzezinski A
    Obstet Gynecol Surv; 1999 Apr; 54(4):272-8. PubMed ID: 10198932
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term "protective" effect of aromatase inhibitors on the endometrium of postmenopausal breast cancer patients.
    Markovitch O; Tepper R; Fishman A; Aviram R; Cohen I
    Breast Cancer Res Treat; 2009 Jan; 113(2):321-6. PubMed ID: 18297393
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer.
    Langan-Fahey SM; Tormey DC; Jordan VC
    Eur J Cancer; 1990; 26(8):883-8. PubMed ID: 2145931
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.
    ; Forbes JF; Cuzick J; Buzdar A; Howell A; Tobias JS; Baum M
    Lancet Oncol; 2008 Jan; 9(1):45-53. PubMed ID: 18083636
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.